<DOC>
	<DOCNO>NCT00309621</DOCNO>
	<brief_summary>Patients severe chronic hand dermatitis , respond topical treatment , include topical steroid avoidance aggravate factor , treat oral medication alitretinoin . The study aim investigate safety efficacy medication give period 6 month .</brief_summary>
	<brief_title>Safety Efficacy Retinoid Treatment Severe Chronic Hand Dermatitis</brief_title>
	<detailed_description>For severe , chronic hand dermatitis , refractory topical treatment avoidance aggravate factor allergens irritant , register systemic treatment available . Current systemic treatment option consist off-label use systemic immune suppressant , cyclosporine , methotrexate . Severe chronic hand dermatitis debilitate disease , massive impact social life work ability . A huge proportion population suffers decade , job loss frequent consequence . This open-label trial investigates safety efficacy oral alitretinoin 30mg single daily dose 6 month . The trial complementary pivotal efficacy study BAP00089 .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Skin Diseases</mesh_term>
	<mesh_term>Hand Dermatoses</mesh_term>
	<mesh_term>Alitretinoin</mesh_term>
	<criteria>Chronic hand dermatitis , rat severe physician global assessment , present least 6 month , respond avoidance allergen irritant use topical steroid female childbearing potential , unless participate pregnancy prevention program psoriasis active major psychiatric condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Hand Dermatoses ,</keyword>
	<keyword>hand dermatitis</keyword>
	<keyword>hand eczema</keyword>
	<keyword>chronic hand dermatitis</keyword>
	<keyword>retinoid</keyword>
</DOC>